Lunasin abrogates monocytes to endothelial cells.

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Nutritional Science

Background:

• Endothelial inflammation, driven by oxidized low-density lipoprotein (ox-LDL), is key in atherosclerosis development.
• Lunasin, a soy-derived peptide, possesses anti-inflammatory and antioxidant properties.
• The precise mechanism of lunasin in ox-LDL-induced endothelial inflammation requires elucidation.

Purpose of the Study:

• To investigate the protective mechanism of lunasin against ox-LDL-induced endothelial inflammation.
• To determine if lunasin affects monocyte adhesion and inflammatory molecule expression.
• To explore the role of KLF2 and the MEK5/ERK5 pathway in lunasin's action.

Main Methods:

• Utilized THP-1 monocytes and human umbilical vein endothelial cells (HUVECs).
• Assessed monocyte adhesion, expression of adhesion molecules (VCAM-1, E-selectin, ICAM-1), KLF2, eNOS, and PAI-1.
• Investigated the involvement of the MEK5/ERK5 signaling pathway.

Main Results:

• Lunasin significantly reduced ox-LDL-induced monocyte adhesion to HUVECs.
• Lunasin suppressed VCAM-1 and E-selectin expression, but not ICAM-1.
• Lunasin upregulated KLF2 expression, which in turn modulated eNOS and PAI-1 levels, mediated by the MEK5/ERK5 pathway.

Conclusions:

• Lunasin ameliorates ox-LDL-induced endothelial inflammation by enhancing KLF2 expression via the MEK5/ERK5 pathway.
• Lunasin's ability to inhibit monocyte adhesion and modulate inflammatory markers suggests a therapeutic potential.
• Dietary or supplementary lunasin may offer a prophylactic or therapeutic strategy for cardiovascular diseases like atherosclerosis.